Free Trial
OTCMKTS:HYPMY

Hypera 10/26/2023 Earnings Report

Hypera logo
$3.71 0.00 (0.00%)
As of 05/2/2025

Hypera EPS Results

Actual EPS
$0.16
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Hypera Revenue Results

Actual Revenue
$437.96 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Hypera Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Hypera's next earnings date is estimated for Wednesday, July 23, 2025, based on past reporting schedules.

Conference Call Resources

Hypera Earnings Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
Hypera S.A. Reports 2024 Financial Performance
Hypera S.A. (HYPMY) Q4 2024 Earnings Call Transcript
Hypera: Short-Term Pain For Long-Term Gain
See More Hypera Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hypera? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hypera and other key companies, straight to your email.

About Hypera

Hypera (OTCMKTS:HYPMY) operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, balance, Flavonid, histamin, NeoFresh, neolefrin, Neochemistry Vitamins, Neosorum, and Torsilax brand names; and consumer health products under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.

View Hypera Profile

More Earnings Resources from MarketBeat